CLVS

Clovis Oncology Inc.

Price

return (12m)

p/e

-0.05

p/bv

-0.03

DIVIDEND YIELD

0.00%

CLVS price

Clovis Oncology

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CLVS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals CLVS

Valuation

P/E

-0.05

Sector -3.50

Industry -3.50

P/BV

-0.03

Sector 2.01

Industry 2.01

P/Revenue (PSR)

Sector 2.01

Industry 2.01

EV/EBITDA

Sector -223.67

Industry -223.67

EV/EBIT

Sector -47.92

Industry -47.92

P/EBITDA

-0.05

Sector -21.50

Industry -21.50

P/EBIT

-0.05

Sector -28.21

Industry -28.21

P/Total Assets

0.04

Sector 1.19

Industry 1.19

P/Net Current Assets

Sector -10.26

Industry -10.26

P/Working Capital

Sector -167.98

Industry -167.98

EPS

-1.74

Sector -1.79

Industry -1.79

BVPS

-2.89

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

27.02%

Sector 41.30%

Industry 41.30%

EBITDA Margin

-150.40%

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

-156.55%

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

-100.00%

Sector -35.21%

Industry -35.21%

Net Profit Margins

-100.00%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.09

Sector 0.02

Industry 0.02

Profitability

ROE

60.28%

Sector -56.67%

Industry -56.67%

ROA

-72.64%

Sector -59.91%

Industry -59.91%

ROIC

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

Sector -8.06

Industry -8.06

Net Debt / Equity

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

Sector -0.85

Industry -0.85

Equity/Assets

-1.21

Sector 0.46

Industry 0.46

Liabilities/Assets

-1.21

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

-2.21%

Sector -

Industry -

5Y Earnings CAGR

-0.97%

Sector -

Industry -

Fundamentals CLVS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
CLVS Clovis Oncology Inc.	$0.00	-	0.00%	-0.05	-0.03	60.28%	-100.00%
JNJ Johnson & Johnson	$269.99	56.71%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$27.66	23.21%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.96	22.44%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$43.24	-26.07%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$146.87	87.26%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$166.08	10.74%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$63.06	48.20%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$71.40	-50.11%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$385.65	38.85%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$784.85	33.10%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$112.45	44.52%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$874.65	25.89%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$508.34	32.68%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$225.38	52.58%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$990.32	34.42%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$42.02	29.13%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CLVS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Clovis Oncology

Clovis Oncology Inc.

Average Investor10 user rating

4.0 (0 people)

United States

17 years

Founded: 2009

2011

Time since IPO - 15 years

429

Employees

Clovis Oncology Inc. (United States) is listed on the Nasdaq and has a market capitalization of $13.45 million, with shareholders equity totaling $-417.89 million.

The company employs approximately 429 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Clovis Oncology Inc. reported $133.02 million in revenue, generating net income of $-251.90 million.

Key financial metrics include a P/E ratio of -0.05, a price-to-book (P/B) ratio of -0.03, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CLVS.

Market cap

$13.45 million

Net worth

$-417.89 million

$-417,886,000.00

Assets

$346.78 million

$346,775,000.00

Total Shares Outstanding

144.63 million

144,625,000

Average Daily Trading Volume

$4.54 million

$4,537,937.84

Sector

Health Care

Industry

Biotechnology

CLVS

CLVS revenue and profits

Financial Results CLVS

DRAG THE FRAME TO SEE MORE DATA

CLVS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$874.65 25,89% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$225.38 52,58% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$269.99 56,71% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.96 22,44% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$146.87 87,26% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$166.08 9,00% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$27.66 23,21% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$874.65 25,89% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$225.38 52,58% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$269.99 56,71% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.96 22,44% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$146.87 87,26% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$166.08 9,00% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$27.66 23,21% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Clovis Oncology (CLVS) today?

A cotação de Clovis Oncology (CLVS) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Clovis Oncology (CLVS) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Clovis Oncology (CLVS) e dados de ações do Ibovespa e mercados internacionais.

Quando Clovis Oncology (CLVS) paga dividendos?

Clovis Oncology (CLVS) não distribuiu dividendos no último ano.

Is Clovis Oncology (CLVS) a good investment?

Atualmente, Clovis Oncology (CLVS) está cotada a US$ 0.00, com um P/L de -0.05, representando um desvio de -5% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Clovis Oncology (CLVS) stock?

Investir em ações de Clovis Oncology (CLVS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Clovis Oncology (CLVS) yield today?

A rentabilidade de Clovis Oncology (CLVS) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Clovis Oncology (CLVS) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CLVS

Clovis Oncology Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CLVS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING CLVS WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Clovis Oncology

Clovis Oncology Inc.

United States

17 years

2011

429

PROFIT X PRICE CLVS

Financial Results CLVS

CLVS cash flow

Asset, Revenue and Profit Growth - CLVS

CLVS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions